March 3, 2026Open Access

Does intestinal ultrasound combined with visceral adipose tissue more accurately predict primary non-response to infliximab in patients with Crohn’s disease? A prospective, observational study

Key Points

Primary non-response to infliximab can be predicted using early changes in BWT on IUS and visceral adipose tissue measurements.
In this study, 80% of patients with specific ultrasound markers showed a clear response to infliximab treatment.
The approach utilized prospective observational data to assess the combined impact of intestinal ultrasound and adipose tissue on treatment outcomes.
Findings may enable clinicians to personalize treatment plans, enhancing outcomes by better stratification of Crohn’s disease patients.

Abstract

Early change in BWT on IUS combined with baseline VFA is highly predictive of PNR to IFX in CD patients, allowing stratification of patients beneficial from treatment initiation and guiding individualized clinical practice.

Does intestinal ultrasound combined with visceral adipose tissue more accurately predict primary non-response to infliximab in patients with Crohn’s disease? A prospective, observational study

Key Points

Abstract

Cite This Study